



For Immediate Release

Contact: Nicole Cottrill
615.327.7999
ncottrill@seig-pr.com

Date: March 4, 2008

New Contracts, Collaboration Fuel Senopsys Expansion

Pharmaceutical Services Company Adds Senior Staff, Moves to New Location to Accommodate Continued Growth

Woburn, Mass. – Senopsys LLC, a specialty services company dedicated to the development of palatable pharmaceuticals, today announced that it has added new senior staff to its leadership team and moved into a larger facility. These milestones cap a year of significant growth for the company that has included several new projects and a global collaboration agreement with Patheon, Inc.

“I began Senopsys knowing that although improving the palatability of drug products enhances patient compliance, improves health outcomes and drives product sales, few drug makers have the expertise to effectively evaluate or optimize palatability,” said Jeff Worthington, Senopsys’ president and founder. “Senopsys collaborates with drug makers so they can concentrate on clinical and commercial development, while we focus on palatability and ensure that drug products will be acceptable to patients.”

“I’m delighted with our growth,” added Worthington. “The last year has been very exciting for us – filled with new projects and collaborations. Our fee-for-service business model and IP-friendly terms continue to resonate with our clients. We are looking forward to the year ahead.”

Senopsys has welcomed two additional senior professionals with extensive experience in food and pharmaceutical development to its team: **David Tisi** as Technical Director and **Vanik Petrossian** as Principal Scientist.

Tisi is leading pharmaceutical taste assessment and optimization projects at Senopsys. A trained descriptive sensory panelist and skilled formulator, he is experienced in developing palatable foods and pharmaceuticals and applying food technology to the creation of novel dosage forms. Tisi came to Senopsys from TIAX LLC where he managed and executed projects to improve the sensory quality of food and drug products.

Petrossian brings more than 30 years of experience in food and pharmaceutical product development to Senopsys. He is widely regarded as a leading expert in the taste masking of drug products. He joins the company following a 24-year tenure at Arthur D. Little and its successor company, TIAX LLC.

In addition, Senopsys has moved to a larger facility at West Cummings Park Medical City in Woburn, Massachusetts that features an expanded formulation suite, sensory analysis laboratory and offices that will allow the company to accommodate its continued growth.

Other notable milestones for Senopsys include:

- **Collaboration with Patheon:** In June 2007, Senopsys began a collaboration with Patheon, a leading global provider of drug development and manufacturing services, to accelerate the development of palatable drug products. The companies are actively collaborating on projects with global pharmaceutical clients and pursuing new contracts.
- **New Contracts:** Senopsys signed development contracts with several pharmaceutical, biotechnology and drug delivery companies in the past year:
 - Taste Optimization of Investigational New Drugs: Senopsys is working to create palatable dosage forms of two antivirals – a pediatric chewable tablet and an adult liquid.
 - New Dosage Forms of Marketed Drugs: The company is working on several dosage form line extensions of marketed drugs including an oral spray, orally disintegrating tablet and pediatric oral suspension.

Senopsys uses proprietary sensory assessment tools to quantitatively measure the taste masking challenge of drug substances and the palatability of drug products. Senopsys then applies its knowledge of flavor construction, excipient functionality and processing technology to develop palatable dosage forms of drugs to meet the needs of specific patient populations.

The company has particular experience in developing palatable drug formulations and dosage forms for children. This is an important issue as Congress recently reauthorized the Food and Drug Administration (FDA) to require drug manufacturers to submit a pediatric assessment as part of a new drug application, and grant additional marketing exclusivity to drug manufacturers that submit pediatric use studies.

For further information about Senopsys, please visit www.senopsys.com or contact the company at info@senopsys.com or 781-935-7450.

###